Please login to the form below

Not currently logged in


This page shows the latest TCR-T news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim and 3T Biosciences in cancer research agreement

Boehringer Ingelheim and 3T Biosciences in cancer research agreement

The partnership will see Boehringer input its patient-derived T-cell receptor (TCR) data into 3T’s discovery platform, 3T TRACE, with the aim of identifying novel antigen targets for cancer ... TCR-T assets from Stanford University to rapidly expand

Latest news

More from news
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • Deal Watch September 2016 Deal Watch September 2016

    1, 695. Medigene /Bluebird bio. Licence. Development and commercialisation of T cell receptor (TCR) immunotherapies against four targets, P1 ready, includes upfront of $15m. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies

  • Deal Watch February 2016 Deal Watch February 2016

    The ARCUS technology enables the production of CAR T-cells derived from healthy donors (i.e. ... licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting

  • Pharma deals in June 2015 Pharma deals in June 2015

    therapeutic strategies, and initially on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies. ... Acquisition - business. 1, 153. Juno Therapeutics/ Celgene Corporation. 10-yr immunotherapy collaboration - CAR-T and T Cell

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    526. Adaptimmune/ GSK. Co-development and option. TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2). ... Collaboration. Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at multiple selected oncology

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...